In vitro studies have demonstrated that AMPK activators, such as metformin and 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside, can arrest the cell cycle and inhibit the proliferation of breast [46], hepatic [47], and prostate cancer cells [53]. This evidence concerns the gene PRKAA1 and prostate cancer.